Published on 30/11/2025

Complex CQAs in Biologics/ATMP: Potency, Identity, and Purity

In the realm of pharmaceuticals, particularly with Biologics and Advanced Therapy Medicinal Products (ATMPs), the critical quality attributes (CQAs) surrounding potency, identity, and purity have become increasingly complex. Regulatory guidelines such as ICH Q5A(R2), FDA process validation requirements, and the new aseptic controls outlined in Annex 1 have necessitated a structured approach to validation in these sectors. This article aims to provide a comprehensive tutorial for professionals seeking to navigate the intricacies of CQAs, particularly those related to viral clearance validation, through step-by-step methodologies.

Understanding CQAs in Biologics and ATMPs

Critical Quality Attributes (CQAs) are defined as physical, chemical, biological, or microbiological properties or characteristics that must be controlled to ensure product quality. For Biologics and ATMPs, key CQAs include potency, identity, and purity, which must meet stringent regulatory expectations to guarantee patient safety and product efficacy.

1. **Potency:** Refers to the ability of the product to elicit the desired biological effect. In several cases, potency assays must be validated against standards to ensure reproducibility and accuracy.

2. **Identity:** This attribute verifies the correct identity of the active substance in the product, which is crucial to ensure that the correct biological response is triggered upon administration.

3. **Purity:** This involves the quantification of impurities that may affect not only the efficacy but also the safety of the product. Impurities can arise from various sources, including the manufacturing process or degradation over time.

In the case of complex biologics, these CQAs can exhibit significant variability, necessitating robust methods for their assessment.

Developing a Validation Strategy

Creating a validation strategy for CQAs involves several key steps:

1. Plan: Begin by laying the groundwork. This includes defining the scope of validation, understanding regulatory requirements, and identifying potential risks related to CQAs.
2. Design: Utilize tools such as risk assessments to outline potential failure modes in the production processes. This will inform your validation efforts, allowing for a targeted approach to complex CQAs.
3. Execute: Carry out the validation plan. This involves executing experiments, analyzing data, and ensuring compliance with both internal and regulatory standards.
4. Review: After execution, conduct a thorough review of the data collected, confirming that all CQAs have been met according to predefined acceptance criteria.

By carefully executing each of these phases, you surround the validation of complex CQAs with scientific rigor and adherence to regulatory expectations.

Aseptic Controls and the Role of Annex 1

The latest draft of Annex 1 has emphasized the importance of implementing stringent aseptic processing controls to avoid contamination in the manufacture of sterile products, particularly ATMPs. Key aspects include:

• **Use of Closed Systems:** Closed systems limit exposure to potential contaminants, which is vital during the production of biologics.
• **Single-Use Systems:** These systems have gained popularity as they reduce the risk of cross-contamination and simplify cleaning validation processes.
• **Environmental Monitoring:** Continuous monitoring of the environment during production is crucial to maintain aseptic conditions.

To align with these requirements, validation efforts must include rigorous testing regimes to ensure that environmental controls meet targeted cleanliness levels. This often involves executing spiking studies to further investigate the efficacy of controls in preventing contamination.

Viral Clearance Validation

Viral clearance validation is a critical aspect of the safety and quality assurance process in biologics and ATMPs. The validation process should cover:

• Assessment of Raw Materials: Ensure all raw materials are sourced from reliable suppliers with robust control measures in place.
• Spiking Studies: These involve the intentional introduction of viral particles into the manufacturing process to assess the efficacy of viral clearance steps. The results assist in determining the capacity of the manufacturing process to effectively remove or inactivate viruses.
• Trend Analysis: Continuous monitoring of viral clearance over time to identify potential variations or concerns, adjusting the process accordingly.

The integration of these studies is critical, especially when considering new manufacturing technologies such as single-use and closed systems, which can alter traditional viral clearance methodologies.

Chain of Identity and Custody in Validation

In accordance with the regulatory expectations, establishing a robust chain of identity (COI) and chain of custody (COC) is essential in ensuring that every component used in the manufacturing process is tracked and validated. This ensures:

• **Integrity of Information:** Documenting every step of the materials verification process is vital for addressing any discrepancies quickly.
• **Traceability:** All product components must be traceable back to approved sources and validated processes.
• **Documentation Control:** Efficient management of documents through a system that is compliant with regulatory expectations is fundamental.

Through a comprehensive review and monitoring of the chain of identity, organizations can significantly minimize the risks associated with variability in CQAs.

Tailoring Process Performance Qualification (PPQ) and Continuous Process Verification (CPV) for ATMPs

Establishing a robust qualification and verification process is essential, particularly for ATMPs. Key considerations include:

1. Defining Acceptance Criteria: Establish stringent performance criteria related to CQAs—particularly potency, identity, and purity—based on regulatory guidelines.
2. PPQ Design: Execute process performance qualification in line with the designed facilities and processes to ensure operational consistency.
3. CPV Implementation: Set up continuous monitoring systems to assess process performance over time, providing early detection of potential deviations.

The successful integration of PPQ and CPV strategies contributes significantly to ensuring that manufactured ATMPs consistently meet quality standards.

Conclusion

As the landscape for biologics and ATMPs continues to evolve, so too does the need for comprehensive and scientific approaches to validating CQAs. Understanding key areas such as potency, identity, and purity is fundamental in safeguarding patient safety and product efficacy.

Employing robust strategies encompassing risk assessment, aseptic controls, viral clearance validation, and an established chain of identity will empower professionals in the pharmaceutical industry to navigate the complexities associated with CQAs effectively.

Ultimately, aligning validation strategies with regulatory expectations and embracing innovations such as closed and single-use systems will enable organizations to maintain compliance and ensure the delivery of safe, effective products.